Furthermore, California has proposed cuts designed to force many sufferers off the program. While funding reductions have continued, medication costs have exploded. Since 1996, medication spending by ADAPs provides increased by over 617 percent, a lot more than the rate of ADAP individual growth more than the same period twice. For instance, Tibotec’s key AIDS drug Prezista costs over $13,200 per patient each year; BMS’ medication Reyataz costs over $12,900 per patient each year; and, Merck’s Isentress costs over $13,400 per patient per year.It generally does not get much more beneficial than that.’ The four papers featuring Elekta technology are: Poor Pulmonary Function isn’t Associated with Increased Rates of Toxicity or Reduced Overall Survival after Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer: Outcomes of a Multi-Institutional Analysis: Matthias Guckenberger, M.D., Jose Belderbos, M.D., Ph.D., Andrew Wish, M.D., Larry L.